Financial News
Grünenthal's proprietary NaV 1.8 inhibitor enters clinical development
February 18, 2026 at 04:30 AM EST
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
(PRLeap.com) Aachen, Germany, 18 February 2026 - Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in the second half of 2026. The Phase I trial will involve 70 healthy volunteers and comprises a Single Ascending Dose and a Multiple Ascending Dose part. It aims to assess the safety and tolerability profile and the pharmacokinetic characteristics of the investigational medicine. In addition, the trial will generate initial insights into the compound's pharmacology through a cold-pressor test.
"Inhibition of NaV 1.8 offers an exciting opportunity to provide patients with urgently needed non-opioid pain therapies," says Uli Brödl, Chief Scientific Officer, Grünenthal. "While we have seen the first medicine targeting NaV 1.8 receive FDA approval last year, we are committed to driving further innovation in this field where advanced assets may provide enhanced patient outcomes by blocking NaV 1.8 more comprehensively."
About voltage-gated sodium channels (NaV)
There are a total of nine different NaV channels in the human body. The NaV 1.8 channel is a clinically and genetically validated pain target, as the channel plays a significant role in triggering excitatory signals in nociceptive neurons, which the human brain perceives as pain. Blocking the NaV 1.8 channel to suppress or prevent its excitatory signalling will provide a significant analgesic effect across a range of chronic and acute pain conditions.
About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better - and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2024, Grünenthal employed around 4,300 people and achieved revenues of �1.8 billion.
More information: https://www.grunenthal.com
Follow us on: LinkedIn: Grunenthal Group
Instagram: grunenthal
Click here for our Grünenthal Report 2024/2025
GET IN TOUCH
Maren Thurow
Grünenthal Group
---
You can see the original version and more on PRLeap here: http://www.prleap.com/pr/310084/grunenthals-proprietary-nav-18-inhibitor-enters-clinical-development-
Report this content
If you believe this article contains misleading, harmful, or spam content, please let us know.
Report this articleMore News
View More
OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings ↗
Today 11:15 EDT
Meta and Tesla Are Rebounding From Oversold Levels—Now What? ↗
Today 10:05 EDT
Recent Quotes
View More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
